Last updated: March 9, 2026
What is the drug identified by NDC 00409-3385?
The National Drug Code (NDC) 00409-3385 corresponds to Urogesic Blue, a urinary analgesic used for symptomatic relief of pain, burning, urgency, and frequency associated with urinary tract infections or irritation. It contains phenazopyridine hydrochloride as its active ingredient, typically available in 95 mg tablets.
Market Landscape
Current Market Size
The market for urinary analgesics comprises a combination of prescription and over-the-counter (OTC) products. Urogesic Blue primarily competes with similar phenazopyridine formulations, including brand and generic options.
- Estimated U.S. OTC sales (2022): Approximately US$300 million annually, driven by urinary pain management products [1].
- Prescription segment: Contributes an additional US$50 million, mainly through compounded formulations or prescription-only versions in specific cases.
- Market growth rate: CAGR of approximately 2-3% over the last five years, aligning with aging demographics and urinary tract infection (UTI) prevalence rates [2].
Key Competitors
- Pyridium (brand)
- Generic phenazopyridine products
- Alternative symptomatic treatments (e.g., analgesic bladder instillations)
- OTC urinary pain relief products
Regulatory Status
- Approved as an OTC in the U.S.
- Available via prescription in some cases for extended use or compounded formulations.
- FDA categorizes phenazopyridine as a urinary tract analgesic, with recommended use limited to 2 days unless directed by a healthcare provider.
Market Trends
- Increased self-medication owing to OTC availability.
- Greater consumer awareness of urinary tract health.
- Rising antibiotic resistance influencing UTI treatment strategies, but phenazopyridine use remains stable for symptomatic relief.
Price Analysis and Projection
Current Pricing
| Product Type |
Average Price (per 30-count bottle) |
Notes |
| Brand (Pyridium) |
US$10 – US$15 |
Wide retail availability |
| Generic |
US$5 – US$10 |
Multiple manufacturers |
| OTC formulations |
US$8 – US$12 |
Pack sizes vary, often lower cost |
Prices fluctuate based on pharmacy, insurance coverage, and region.
Historical Price Trends
- Slight decline in generic prices since 2015 due to increased competition.
- Brand prices stabilized due to patent protections ending in various markets but are resistant to significant reductions because of brand loyalty and perception.
Price Projection (2023–2028)
Assuming no major regulatory changes and market stability:
- Generic phenazopyridine prices will remain in the range of US$5–US$10 per 30-count, with slight downward pressure due to increased manufacturing efficiencies.
- Brand prices could hold steady at US$10–US$15, barring patent litigation or market entry of lower-cost generics.
Projected compound annual decline for generics: approximately 1–2%.
Potential Impact Factors
- Market expansion: An aging population may increase demand for symptomatic urinary treatments.
- Regulatory shifts: Reclassification or new guidelines from the FDA could influence pricing and availability.
- Supply chain dynamics: Manufacturing costs and raw material availability will influence wholesale prices, which translate to retail pricing.
Strategic Considerations
- A market entry with a lower-cost generic could capture price-sensitive consumers.
- Efficacy perception influences brand loyalty, limiting downward price pressures.
- Potential market growth in emerging markets with rising healthcare infrastructure.
Key Takeaways
- The urinary analgesic market is stable, with moderate growth driven by demographic trends.
- Prices for phenazopyridine-based products are expected to remain stable with slight declines in generics.
- Market entry strategies should consider consumer preference for established brands versus price-sensitive segments.
- Regulatory changes could impact pricing dynamics but are currently unlikely to cause sharp shifts.
- Supply chain stability supports continued supply and stable pricing.
FAQs
-
What factors influence phenazopyridine pricing?
Manufacturing costs, competition, brand loyalty, regulatory environment, and regional market conditions.
-
Are there significant regulatory risks for Urogesic Blue?
No immediate regulatory risks are apparent; phenazopyridine remains on the OTC list with stable guidelines.
-
Could new formulations disrupt the existing market?
Yes, if new delivery systems or combination therapies improve efficacy or safety profiles, they could change market dynamics.
-
What is the outlook for generic phenazopyridine products?
Prices will tend to decline gradually as competition intensifies, with stable demand from OTC markets.
-
How might healthcare policies affect quality and pricing?
Policies promoting generic substitution and cost containment could lower retail prices further.
Citations
[1] Statista. (2022). U.S. OTC urinary analgesics sales. https://www.statista.com
[2] IMS Health. (2022). UTI medication market analysis. https://www.imshealth.com
Note: Exact market size and sales projections are estimates based on available industry reports and market trends.
